BioSpace News Archive

Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announced the commercial launch of DHIVY, the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in November 2021.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company’s fourth quarter and full year 2021 financial results on Monday, February 28, 2022.

Stablix, Inc. today announced the appointment of Tony Kingsley as Chief Executive Officer.

New Review Article in ESC’s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) Inhibition’s Role in Reducing Cardiovascular Disease Risk.

Asher Biotherapeutics today announced the appointment of Ian T. Clark to its Board of Directors.

CytRx Corporation today highlighted Orphazyme A/S for the treatment of Niemann-Pick disease type C (“NPC”). CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.

Curebase, a company committed to democratizing access to clinical studies, has named Dr. Aaron Kamauu and Dr. Amir Lahav to the Curebase Advisory Board.

Veru Inc. (NASDAQ: VERU) today announced that the Independent Data Monitoring Committee (IDMC) has conducted a planned conditional power analysis of the first 75 randomized patients in the Global Phase 3 COVID-19.

Coherus BioSciences, Inc., announced that effective Feb. 9, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 236,500 shares of the common stock of the Company to newly hired employees with a per share exercise price of $12.44, the closing trading price on the grant date.

MedVadis Research announced today that it is broadening its studies to address Alzheimer’s disease and other dementias.